Across bulk transcriptomics (TCGA/CGGA), single‐cell, spatial, and IHC, we identify TMEM106A as an independent prognostic biomarker in glioma—most pronounced in IDH‐wildtype. This evidence concerns the gene TMEM106A and central nervous system cancer.